Inogen (INGN) Competitors $8.15 +0.21 (+2.58%) As of 02:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends INGN vs. EYE, CBLL, BBNX, BFLY, BVS, EMBC, AXGN, SIBN, AVNS, and IRMDShould you be buying Inogen stock or one of its competitors? The main competitors of Inogen include National Vision (EYE), CeriBell (CBLL), Beta Bionics (BBNX), Butterfly Network (BFLY), Bioventus (BVS), Embecta (EMBC), AxoGen (AXGN), SI-BONE (SIBN), Avanos Medical (AVNS), and Iradimed (IRMD). These companies are all part of the "medical equipment" industry. Inogen vs. National Vision CeriBell Beta Bionics Butterfly Network Bioventus Embecta AxoGen SI-BONE Avanos Medical Iradimed Inogen (NASDAQ:INGN) and National Vision (NASDAQ:EYE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, community ranking, dividends, valuation, institutional ownership and earnings. Is INGN or EYE more profitable? National Vision has a net margin of -0.81% compared to Inogen's net margin of -15.89%. National Vision's return on equity of 3.52% beat Inogen's return on equity.Company Net Margins Return on Equity Return on Assets Inogen-15.89% -27.38% -16.77% National Vision -0.81%3.52%1.39% Which has more risk and volatility, INGN or EYE? Inogen has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, National Vision has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Does the MarketBeat Community prefer INGN or EYE? Inogen received 135 more outperform votes than National Vision when rated by MarketBeat users. Likewise, 68.97% of users gave Inogen an outperform vote while only 65.13% of users gave National Vision an outperform vote. CompanyUnderperformOutperformInogenOutperform Votes38968.97% Underperform Votes17531.03% National VisionOutperform Votes25465.13% Underperform Votes13634.87% Which has higher valuation & earnings, INGN or EYE? National Vision has higher revenue and earnings than Inogen. National Vision is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInogen$335.71M0.56-$102.45M-$1.52-5.23National Vision$2.18B0.45-$65.90M-$0.20-61.85 Does the media refer more to INGN or EYE? In the previous week, Inogen had 8 more articles in the media than National Vision. MarketBeat recorded 26 mentions for Inogen and 18 mentions for National Vision. National Vision's average media sentiment score of 0.78 beat Inogen's score of 0.23 indicating that National Vision is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inogen 2 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral National Vision 3 Very Positive mention(s) 9 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of INGN or EYE? 89.9% of Inogen shares are owned by institutional investors. 1.0% of Inogen shares are owned by insiders. Comparatively, 2.3% of National Vision shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts prefer INGN or EYE? Inogen presently has a consensus target price of $7.00, indicating a potential downside of 11.95%. National Vision has a consensus target price of $13.60, indicating a potential upside of 9.94%. Given National Vision's stronger consensus rating and higher probable upside, analysts plainly believe National Vision is more favorable than Inogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00National Vision 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 SummaryNational Vision beats Inogen on 12 of the 18 factors compared between the two stocks. Get Inogen News Delivered to You Automatically Sign up to receive the latest news and ratings for INGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INGN vs. The Competition Export to ExcelMetricInogenSurgical appliances & supplies IndustryMedical SectorNASDAQ ExchangeMarket Cap$189.35M$9.61B$5.76B$8.47BDividend YieldN/A1.39%4.74%3.94%P/E Ratio-3.5318.5125.1819.05Price / Sales0.5646.26383.54108.76Price / CashN/A19.6738.0634.58Price / Book0.905.697.454.39Net Income-$102.45M$284.66M$3.19B$246.62M7 Day Performance-19.78%-3.69%-3.45%-3.46%1 Month Performance-32.74%-5.88%-3.96%-5.01%1 Year Performance26.39%-17.44%11.56%6.46% Inogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INGNInogen3.3882 of 5 stars$8.16+2.6%$7.00-14.2%-14.9%$194.09M$335.71M-3.621,030Analyst ForecastShort Interest ↓EYENational Vision1.6814 of 5 stars$11.69-0.1%$13.40+14.7%-46.5%$919.41M$2.18B-58.3713,998Analyst ForecastNews CoveragePositive NewsCBLLCeriBellN/A$25.35+2.7%$32.60+28.6%N/A$903.30M$60.04M0.00N/AEarnings ReportAnalyst ForecastAnalyst RevisionNews CoverageBBNXBeta BionicsN/A$20.63+0.3%$24.83+20.4%N/A$884.20MN/A0.00294Analyst RevisionBFLYButterfly Network1.5586 of 5 stars$4.02-6.6%$3.00-25.3%+149.7%$857.57M$65.90M-8.75460Earnings ReportNews CoverageGap DownBVSBioventus3.2378 of 5 stars$10.08+0.6%$15.00+48.9%+97.4%$817.18M$512.34M-16.511,200News CoverageEMBCEmbecta4.6152 of 5 stars$13.77-2.4%$23.00+67.1%-7.0%$805.16M$1.11B13.852,100Short Interest ↑AXGNAxoGen1.2162 of 5 stars$17.97-0.2%$18.33+2.0%+82.1%$793.46M$180.86M-56.34450Analyst ForecastAnalyst RevisionSIBNSI-BONE4.2294 of 5 stars$17.55-1.6%$23.00+31.1%+0.3%$734.96M$157.04M-19.05350Earnings ReportAnalyst ForecastAnalyst RevisionAVNSAvanos Medical2.2916 of 5 stars$15.73+1.8%N/A-21.2%$722.58M$681.50M46.243,771Earnings ReportNews CoverageIRMDIradimed4.9328 of 5 stars$55.14-1.7%$72.00+30.6%+26.5%$701.67M$73.24M36.91110 Related Companies and Tools Related Companies National Vision Alternatives CeriBell Alternatives Beta Bionics Alternatives Butterfly Network Alternatives Bioventus Alternatives Embecta Alternatives AxoGen Alternatives SI-BONE Alternatives Avanos Medical Alternatives Iradimed Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INGN) was last updated on 2/28/2025 by MarketBeat.com Staff From Our Partners🚨My flagship system for just $0.99Right now, you can get a full year of my flagship trading program, Stealth Trades, for just 99 cents…Traders Agency | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhy 2026 will be a disaster for many AmericansWall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inogen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.